☰

Dompé Farmaceutici S.p.A.

Connecting discovery, manufacturing and regulatory evidence

Industry
Pharmaceuticals and Biotechnology
Headquarters
Milan, Italy
Public information as of
February 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Dompé Farmaceutici S.p.A.'s published strategy and is not endorsed by, or produced in cooperation with, Dompé Farmaceutici S.p.A.. Company website

Strategic priorities

Dompé combines a primary and specialty care portfolio with biotechnology research and production centred on recombinant human nerve growth factor (rhNGF). Its 2024 revenue was reported at €1.234 billion, with about 950 employees, and research and development investment increased by 33 percent that year.

The L'Aquila site integrates research, oral solid dose and liquid medicine production, and rhNGF bioprocessing. More than €200 million has been invested there since 1993, and a 2025 expansion added about 600 square metres of production capacity and a high-capacity liquid line with advanced controls while critical-utility supervisory control and data acquisition systems entered modernization.

Dompé is also the first private company to use Leonardo, one of Europe's leading supercomputers, through its Exscalate drug-discovery platform. The practical digital task is to connect that computational capability with physical process, laboratory and quality data while maintaining inspection-ready evidence for the Italian Medicines Agency, US Food and Drug Administration and other regulators across roughly 40 markets.

Challenges we see

  • Digital Manufacturing

    Modernizing critical-utility controls while production continues

    Critical-utility supervisory control and data acquisition systems at the L'Aquila facility are being modernized to address obsolescence and integrate new technologies alongside the site's production expansion.

    A live-site modernization has to preserve validated control and complete records while creating a standards-based data path from utilities and production equipment to plant and enterprise systems.

  • Digital Integration

    Connecting computational discovery to physical process development

    The Exscalate platform uses high-performance computing and artificial intelligence for virtual molecular discovery, while biotechnology production at L'Aquila depends on physical fermentation, purification and formulation parameters.

    Moving from a molecular model to a reproducible process requires shared definitions and traceable transformations between computational outputs, development experiments and manufacturing parameters.

  • Operations Manufacturing

    Protecting cell banks and biologics cold chains

    Master and Working Cell Banks are stored in cryogenic systems at temperatures as low as -173°C, while rhNGF materials use -20°C storage and distribution conditions.

    For biological assets that cannot be replaced quickly, continuous condition records and early indicators of equipment degradation provide more decision time than threshold alarms alone.

  • Operations Manufacturing

    Extending batch visibility through fill and finish

    Dompé performs upstream and downstream biotechnology processes in-house, while external partners undertake aseptic filling and sterilization for parts of the value chain.

    When batch custody crosses an organisational boundary, common identifiers and shared quality records are needed to keep handling conditions, process evidence and release status readable end to end.

  • Operations Operations

    Scaling specialist work across sites and agencies

    About 50 percent of regional demand for science, technology, engineering and mathematics profiles was reported as unmet, while Dompé manages manufacturing, research and regulatory activity across Italy, the United States, China and other markets.

    As specialist review demand grows faster than available capacity, structured automation and reusable evidence can reserve expert time for scientific, quality and regulatory judgement.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Standards-based control architecture for L'Aquila

    Critical-utility control systems are being modernized while the site expands production, so new and established equipment must exchange data without interrupting validated operations.

    Define an OPC UA (Open Platform Communications Unified Architecture) architecture, equipment data contracts, network segmentation and validation package that can be introduced in stages across the live site.

    • Dompé L'Aquila production and research site profile
    • Dompé company history and 2025 production expansion

  2. Shared model from Exscalate to process development

    Computational discovery outputs and physical fermentation, purification and formulation data use different structures and move through separate software environments.

    Create an ontology connecting molecule, experiment, material, process parameter and quality attribute so computational results and development records can be compared and traced in one model.

    • Dompé and CINECA Leonardo supercomputer partnership
    • Dompé Exscalate and TechBio strategy materials

  3. Predictive monitoring for cryogenic assets

    Cell banks are held at temperatures down to -173°C, where equipment or power degradation can reduce the time available to protect irreplaceable biological material.

    Combine temperature, power and equipment-health signals in a continuous monitored record, with trend-based alerts and tested escalation workflows before critical thresholds are reached.

    • Dompé L'Aquila biotechnology production profile

  4. Partner-connected batch traceability

    Aseptic filling and sterilization are performed by external partners, placing part of the batch record and handling-condition history outside Dompé's direct systems.

    Use secure application programming interfaces and shared batch identifiers to exchange status, environmental and quality records with partners while preserving source ownership and audit trails.

    • Dompé L'Aquila value-chain and fill-and-finish profile

  5. Assisted preparation of regulatory study documents

    Clinical study reports, marketing-authorisation updates and renewals require recurring assembly and cross-checking of controlled evidence for FDA, EMA, AIFA and other agency processes.

    Deploy narrowly scoped agents to assemble first drafts from approved sources, check submissions against agency and company templates, and map changes to affected documents, with named reviewers approving every output.

    • Dompé global regulatory footprint and rare-disease pipeline materials
    • Dompé NAION priority review programme information

What we'd propose

  • Digital CDMO

    Validated IT and OT modernization for L'Aquila

    A staged architecture and implementation programme for critical utilities and production equipment, connecting established and new controls through documented standards while preserving validated operation.

    • Control and data architecture

      One standards-based plant design

      Define OPC UA information models, interfaces between supervisory control and enterprise systems, and migration boundaries so each modernization stage contributes to one target architecture.

    • Secure network segmentation

      Protected paths between plant systems

      Design zones, conduits and remote-access controls aligned with IEC 62443 so analytics access does not flatten the boundary between operational and enterprise networks.

    • Validation and phased migration

      Evidence for each transition step

      Build requirements, traceability and test evidence into the migration plan so legacy and replacement systems can coexist during commissioning without breaking the validated record.

    • Modernization proceeds in manageable stages while production continues.
    • New equipment arrives with documented data interfaces rather than one-off integration work.
    • Security and validation evidence are produced with the architecture, not after commissioning.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    One data model for computational and process development

    An ontology-based platform connecting Exscalate outputs with development experiments and process parameters so digital discovery and physical development share traceable scientific context.

    • Scientific and process ontology

      Shared definitions across discovery and development

      Model molecules, assays, experiments, materials, process steps, parameters and quality attributes with explicit relationships and controlled identifiers.

    • Validated data pipelines

      Traceable movement between systems

      Ingest computational, laboratory and process-development records with schema checks, lineage and versioning so each transformation can be inspected and reproduced.

    • Cross-domain analysis

      Discovery and process evidence queried together

      Provide retrieval and analytics over the shared model so scientists can compare computational predictions with experimental and process outcomes without separate extracts.

    • Computational findings retain their context as they move into physical development.
    • Repeated manual mapping between discovery and process systems is replaced by one governed model.
    • Experimental outcomes can feed future model refinement through a traceable data path.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Predictive protection for cryogenic biological assets

    A monitored equipment-health and environmental record for cryogenic storage, combining condition signals with trend alerts and rehearsed response workflows to increase intervention time.

    • Condition data capture

      Temperature, power and equipment signals together

      Connect cryogenic storage and supporting utilities to record temperature, power quality, compressor or vessel health and alarm state with synchronized timestamps.

    • Trend-based warning

      Earlier indications than threshold alarms

      Model normal equipment behaviour and flag sustained drift or correlated anomalies, giving operations time to inspect and intervene before storage conditions reach critical limits.

    • Response evidence

      Tested escalation and audit records

      Digitize alert routing, acknowledgement, contingency actions and periodic recovery drills so response readiness and each real event are documented end to end.

    • Equipment drift is visible before a critical temperature threshold is crossed.
    • Environmental and response evidence is continuous and inspection-readable.
    • Contingency procedures can be tested against realistic scenarios without placing cell banks at risk.

    We've done this before

    See how we do Digital Lab
  • Agents

    AI agents for regulatory and clinical documentation

    Reviewable agents for recurring FDA, EMA and AIFA documentation work, assembling drafts from controlled sources, checking completeness and identifying affected records while named specialists retain every approval decision.

    • Controlled-source drafting

      First drafts grounded in approved evidence

      Assemble clinical study, variation and marketing-authorisation renewal drafts from designated source records with citations back to each claim and data point.

    • Template and consistency checks

      Submission gaps found before review

      Check sections, terminology, dates, tables and cross-references against agency guidance and Dompé templates before a document enters the specialist review queue.

    • Change impact mapping

      Affected documents identified together

      Trace a changed study result, specification or regulatory requirement across controlled documents and rank the records requiring review or revision.

    • Specialists begin from a sourced draft rather than assembling repeated background sections.
    • Completeness and consistency checks happen before formal review.
    • Every generated passage remains traceable to controlled evidence and a named approver.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Dompé Farmaceutici S.p.A.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
IT and OT integration 35 → 80
Critical-utility control modernization and the new liquid line create a clear path to standards-based plant connectivity, while the live site's mixed equipment generations require staged implementation.
Data analytics and AI 55 → 90
Exscalate and access to Leonardo establish strong computational capability; the next step is a governed connection from computational outputs to experimental and manufacturing data.
Laboratory digitalization 40 → 85
L'Aquila operates chemical, microbiological and packaging-material laboratories, and direct instrument-to-system data flows would make quality evidence more continuous and reusable.
Supply chain visibility 45 → 80
Internal biotechnology operations and external aseptic processing belong to one batch record, making shared identifiers and partner data exchange central to end-to-end traceability.
Predictive maintenance 30 → 75
Temperature alarms protect cryogenic storage today; combining equipment-health and environmental trends would provide earlier warning and a stronger response record.
Regulatory automation 50 → 85
Dompé manages approvals and ongoing evidence across roughly 40 markets, giving recurring document assembly, completeness checks and change-impact review a strong automation case.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of February 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Dompé Farmaceutici S.p.A., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].